Granulocyte colony-stimulating factor reverses cytopenia and may permit cytogenetic responses in patients with chronic myeloid leukemia treated with imatinib mesylate

David Marin, Sarah Marktel, Nicola Foot, Marco Bua, Eduardo Olavarria, John M. Galdman, Jane F. Apperley

Research output: Contribution to journalArticle

Abstract

Imatinib mesylate induces major or complete cytogenetic responses in the majority of patients with chronic myeloid leukemia (CML) in chronic phase. However, 15-40% of patients develop neutropenia and/or thrombocytopenia that makes it necessary to reduce the dosage or to interrupt treatment. Patients with recurrent cytopenias may be less likely to obtain cytogenetic responses. We speculated that low doses of granulocyte colony-stimulating factor (G-CSF) in conjunction with imatinib might offer clinical benefit. Eleven patients with CML in chronic (n=9) or accelerated (n=2) phase who could not tolerate 300 mg/day and had no cytogenetic response after 6 months of imatinib treatment received G-CSF in combination with imatinib. Ten of the 11 patients could then tolerate doses of imatinib equal to or greater than 300 mg/day and 7 patients achieved major (n=6) or complete (n=1) cytogenetic responses. We conclude that G-CSF reverses the hematologic toxicity of imatinib and may thereby increase the proportion of cytogenetic responses.

Original languageEnglish
Pages (from-to)227-229
Number of pages3
JournalHaematologica
Volume88
Issue number2
Publication statusPublished - Feb 1 2003

Fingerprint

Granulocyte Colony-Stimulating Factor
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cytogenetics
Leukemia, Myeloid, Chronic Phase
Neutropenia
Thrombocytopenia
Imatinib Mesylate
Therapeutics

Keywords

  • G-CSF cytopenia
  • Imatinib

ASJC Scopus subject areas

  • Hematology

Cite this

Granulocyte colony-stimulating factor reverses cytopenia and may permit cytogenetic responses in patients with chronic myeloid leukemia treated with imatinib mesylate. / Marin, David; Marktel, Sarah; Foot, Nicola; Bua, Marco; Olavarria, Eduardo; Galdman, John M.; Apperley, Jane F.

In: Haematologica, Vol. 88, No. 2, 01.02.2003, p. 227-229.

Research output: Contribution to journalArticle

Marin, David ; Marktel, Sarah ; Foot, Nicola ; Bua, Marco ; Olavarria, Eduardo ; Galdman, John M. ; Apperley, Jane F. / Granulocyte colony-stimulating factor reverses cytopenia and may permit cytogenetic responses in patients with chronic myeloid leukemia treated with imatinib mesylate. In: Haematologica. 2003 ; Vol. 88, No. 2. pp. 227-229.
@article{c8078b5acf614e5a98a970db48a3f063,
title = "Granulocyte colony-stimulating factor reverses cytopenia and may permit cytogenetic responses in patients with chronic myeloid leukemia treated with imatinib mesylate",
abstract = "Imatinib mesylate induces major or complete cytogenetic responses in the majority of patients with chronic myeloid leukemia (CML) in chronic phase. However, 15-40{\%} of patients develop neutropenia and/or thrombocytopenia that makes it necessary to reduce the dosage or to interrupt treatment. Patients with recurrent cytopenias may be less likely to obtain cytogenetic responses. We speculated that low doses of granulocyte colony-stimulating factor (G-CSF) in conjunction with imatinib might offer clinical benefit. Eleven patients with CML in chronic (n=9) or accelerated (n=2) phase who could not tolerate 300 mg/day and had no cytogenetic response after 6 months of imatinib treatment received G-CSF in combination with imatinib. Ten of the 11 patients could then tolerate doses of imatinib equal to or greater than 300 mg/day and 7 patients achieved major (n=6) or complete (n=1) cytogenetic responses. We conclude that G-CSF reverses the hematologic toxicity of imatinib and may thereby increase the proportion of cytogenetic responses.",
keywords = "G-CSF cytopenia, Imatinib",
author = "David Marin and Sarah Marktel and Nicola Foot and Marco Bua and Eduardo Olavarria and Galdman, {John M.} and Apperley, {Jane F.}",
year = "2003",
month = "2",
day = "1",
language = "English",
volume = "88",
pages = "227--229",
journal = "Haematologica",
issn = "0390-6078",
publisher = "NLM (Medline)",
number = "2",

}

TY - JOUR

T1 - Granulocyte colony-stimulating factor reverses cytopenia and may permit cytogenetic responses in patients with chronic myeloid leukemia treated with imatinib mesylate

AU - Marin, David

AU - Marktel, Sarah

AU - Foot, Nicola

AU - Bua, Marco

AU - Olavarria, Eduardo

AU - Galdman, John M.

AU - Apperley, Jane F.

PY - 2003/2/1

Y1 - 2003/2/1

N2 - Imatinib mesylate induces major or complete cytogenetic responses in the majority of patients with chronic myeloid leukemia (CML) in chronic phase. However, 15-40% of patients develop neutropenia and/or thrombocytopenia that makes it necessary to reduce the dosage or to interrupt treatment. Patients with recurrent cytopenias may be less likely to obtain cytogenetic responses. We speculated that low doses of granulocyte colony-stimulating factor (G-CSF) in conjunction with imatinib might offer clinical benefit. Eleven patients with CML in chronic (n=9) or accelerated (n=2) phase who could not tolerate 300 mg/day and had no cytogenetic response after 6 months of imatinib treatment received G-CSF in combination with imatinib. Ten of the 11 patients could then tolerate doses of imatinib equal to or greater than 300 mg/day and 7 patients achieved major (n=6) or complete (n=1) cytogenetic responses. We conclude that G-CSF reverses the hematologic toxicity of imatinib and may thereby increase the proportion of cytogenetic responses.

AB - Imatinib mesylate induces major or complete cytogenetic responses in the majority of patients with chronic myeloid leukemia (CML) in chronic phase. However, 15-40% of patients develop neutropenia and/or thrombocytopenia that makes it necessary to reduce the dosage or to interrupt treatment. Patients with recurrent cytopenias may be less likely to obtain cytogenetic responses. We speculated that low doses of granulocyte colony-stimulating factor (G-CSF) in conjunction with imatinib might offer clinical benefit. Eleven patients with CML in chronic (n=9) or accelerated (n=2) phase who could not tolerate 300 mg/day and had no cytogenetic response after 6 months of imatinib treatment received G-CSF in combination with imatinib. Ten of the 11 patients could then tolerate doses of imatinib equal to or greater than 300 mg/day and 7 patients achieved major (n=6) or complete (n=1) cytogenetic responses. We conclude that G-CSF reverses the hematologic toxicity of imatinib and may thereby increase the proportion of cytogenetic responses.

KW - G-CSF cytopenia

KW - Imatinib

UR - http://www.scopus.com/inward/record.url?scp=0038460326&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038460326&partnerID=8YFLogxK

M3 - Article

C2 - 12604417

AN - SCOPUS:0038460326

VL - 88

SP - 227

EP - 229

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 2

ER -